InMed Pharmaceuticals Amends Preferred Investment Options
Rhea-AI Summary
InMed Pharmaceuticals (NASDAQ: INM) amended previously issued preferred investment options with Sabby Volatility Warrant Master Fund and affiliates of H.C. Wainwright to change exercise prices to $0.80 per share. The amendments apply to rights to subscribe for up to 2,151,478 shares (Sabby) and 153,236 shares (Wainwright) on a post-consolidation basis. The options were issued in private placements under Section 4(a)(2) and Regulation D. No assurance any options will be exercised.
AI-generated analysis. Not financial advice.
Positive
- Exercise prices unified at $0.80 for all amended Preferred Investment Options
- Aggregate subscription capacity preserved at 2,304,714 post-consolidation shares
Negative
- Potential dilution from up to 2,304,714 shares if all options exercised at $0.80
- No assurance provided that any Preferred Investment Options will be exercised
News Market Reaction – INM
On the day this news was published, INM declined 4.31%, reflecting a moderate negative market reaction. Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $110K from the company's valuation, bringing the market cap to $2.45M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Before the warrant repricing news, INM was up 1.22% while several biotech peers also traded higher: SHPH +0.96%, RDHL +0.98%, PRFX +2.19%, and CPHI +2.56%, with only SBFM at -1.79%. This points to a broader sector bid rather than company-specific momentum.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 27 | Nasdaq compliance notice | Negative | -6.2% | Nasdaq notified INM its bid price fell below the $1.00 minimum threshold. |
| Mar 23 | Preclinical data update | Positive | -6.9% | INM-901 showed dose-dependent neuroinflammation reductions in 3D human brain organoid models. |
| Mar 09 | Pipeline development plan | Positive | -3.7% | Company outlined 2026 priorities to advance INM-901 and INM-089 toward IND and trials. |
| Mar 06 | BayMedica wind-down | Negative | -3.7% | Decision to exit BayMedica’s commercial business and incur one-time costs while refocusing pipeline. |
| Feb 11 | Earnings and update | Negative | -10.1% | Q2 FY2026 results showed net loss, BayMedica revenue decline, and limited cash runway into Q4 2026. |
Positive R&D and development updates have often coincided with negative next-day price moves, while clearly adverse regulatory or operational headlines tended to see aligned downside reactions.
Over the last few months, INM has faced several pressures alongside pipeline progress. A Feb 11 earnings update reported a quarterly net loss and highlighted BayMedica revenue declines, followed by a Mar 6 decision to wind down BayMedica’s commercial operations with about $550,000 in severance and $120,000 in other costs. Despite positive preclinical data for INM-901 and INM-089 reported on Mar 9 and Mar 23, shares fell after those updates, and a Mar 27 Nasdaq minimum bid-price notice also drew a negative reaction. Today’s repricing of preferred investment options adds another capital-structure overhang to this backdrop.
Regulatory & Risk Context
INM has an effective Form S-3 shelf filed on 2026-03-20, allowing it to offer up to $50,000,000 of securities over time. The company has already utilized this shelf via a 424B5 prospectus supplement dated 2026-04-03 for an at-the-market common share program of up to $1,213,648, highlighting ongoing access to equity financing alongside today’s repriced preferred investment options.
Market Pulse Summary
This announcement centers on repricing existing preferred investment options for Sabby and Wainwright affiliates down to $0.80, covering up to 2,151,478 and 153,236 shares, respectively. It comes on top of an at-the-market equity program of up to $1,213,648 and a $50,000,000 Form S-3 shelf. Historically, the stock reacted negatively to both operational changes and regulatory notices, even when pipeline news was positive. Investors may watch execution under the ATM, any exercises of these options, and progress toward addressing Nasdaq’s minimum bid-price requirement.
Key Terms
preferred investment options financial
Section 4(a)(2) regulatory
Regulation D regulatory
Form 8-K regulatory
at-the-market financial
shelf registration statement regulatory
Form S-3 regulatory
AI-generated analysis. Not financial advice.
Vancouver, British Columbia--(Newsfile Corp. - April 27, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announces that it has entered into amending agreements in respect of preferred investment options previously entered into with each of Sabby Volatility Warrant Master Fund, Ltd. ("Sabby") and certain affiliates of H.C. Wainwright & Co., LLC (the "Wainwright Parties").
As previously reported:
- pursuant to the terms of the preferred investment options dated October 26, 2023 and June 26, 2025 (together, the "Sabby Preferred Investment Options"), the Company provided Sabby with the right to subscribe for and purchase from the Company, in the aggregate, up to 2,151,478 common shares in the capital of the Company (on a post-consolidation basis) at an exercise price per common share of
$2.436 , subject to adjustment (the "Sabby Exercise Price"); and
- pursuant to the terms of the preferred investment options dated November 21, 2022, October 26, 2023 and June 26, 2025 issued to the Wainwright Parties (collectively, the "Wainwright Preferred Investment Options", and together with the Sabby Preferred Investment Options, the "Preferred Investment Options"), the Company provided the Wainwright Parties with the right to subscribe for and purchase from the Company, in the aggregate, up to 153,236 common shares in the capital of the Company (on a post-consolidation basis) at exercise prices per common share of
$82.50 ,$20.75 and$3.2013 (in each case, on a post-consolidation basis), respectively, subject to adjustment in each case (collectively, the "Wainwright Exercise Prices").
The Company has entered into: (i) an amending agreement with Sabby in respect of the Sabby Preferred Investment Options to amend the Sabby Exercise Price to
Each of the Preferred Investment Options were offered in private placements pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended, and Regulation D promulgated thereunder. No assurance can be given that any of the Preferred Investment Options will be exercised.
For further information, please see the Company's filings with the Securities and Exchange Commission, including the Company's Current Reports on Form 8-K filed with the Securities and Exchange Commission from time to time.
About InMed
InMed Pharmaceuticals is a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates targeting the CB1/CB2 receptors. InMed's pipeline consists of three separate programs in the treatment of Alzheimer's, ocular and dermatological indications. Together with our subsidiary BayMedica, we are a global leader in the manufacturing, development and commercialization of products based on rare cannabinoids and their proprietary, small molecule drug analogs. For more information, visit www.inmedpharma.com.
Investor Contact:
Colin Clancy
Vice President, Investor Relations
and Corporate Communications
T: +1.604.416.0999
E: ir@inmedpharma.com
Cautionary Note Regarding Forward-Looking Information:
This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities laws. Forward-looking information is based on management's current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Without limiting the foregoing, forward-looking information in this news release includes, but is not limited to, statements about the exercise of the Preferred Investment Options prior to their expiration.
With respect to the forward-looking information contained in this news release, InMed has made numerous assumptions regarding, among other things: the ability to obtain all necessary regulatory approvals on a timely basis, or at all; and continued economic and market stability. While InMed considers these assumptions to be reasonable, these assumptions are inherently subject to significant business, economic, competitive, market and social uncertainties and contingencies. Additionally, there are known and unknown risk factors which could cause InMed's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. A complete discussion of the risks and uncertainties facing InMed's stand-alone business is disclosed in InMed's Annual Report on Form 10-K, InMed's Quarterly Report on Form 10-Q and other filings with the Security and Exchange Commission on www.sec.gov.
All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/294412